Samsung Bioepis’ Byooviz (ranibizumab) biosimilar is set to become the first biosimilar referencing Lucentis (ranibizumab) to hit Europe, following a positive opinion adopted by the European Medicines Agency’s Committee for Medicinal Products for Human Use.
The CHMP has announced it has recommended the European Commission grant Samsung Bioepis a landmark pan-European marketing authorization for its biosimilar treatment for wet age-related macular degeneration
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?